{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:59:07Z","timestamp":1785214747917,"version":"3.55.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose:<\/jats:title>\n                    <jats:p>\n                      Metabotropic glutamate receptors are class C G-protein-coupled receptors that respond to the neurotransmitter glutamate. In particular, metabotropic glutamate receptor 5 (mGluR5) has been a valuable drug target for the management of psychiatric and neurodegenerative disorders such as fragile X syndrome, autism, depression, anxiety, addiction, and movement disorders through negative allosteric modulators (NAMs). Despite the discovery of several NAMs, limited clinical efficacy was observed, thus preventing them from reaching the clinical stage. Natural products are indispensable, with a plethora of pharmacological actions. This study aimed to identify potential natural compounds as novel natural NAMs modulating mGluR5 using a comprehensive\n                      <jats:italic toggle=\"yes\">in silico<\/jats:italic>\n                      approach.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental approach:<\/jats:title>\n                    <jats:p>Utilizing receptor-based pharmacophore modelling, we virtually screened a natural library comprised of ~1.2 million compounds to study their molecular binding behavior against mGluR5. Furthermore, the best hits were evaluated using the end-point method (molecular mechanics Poisson-Boltzmann surface area), molecular dynamics (MD) simulations, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings\/Results:<\/jats:title>\n                    <jats:p>Based on the augmented computational modelling, we identified four promising natural hits-3\u2019-HPS, gigantol, isorhapontigenin, and coclaurine that demonstrated higher affinities than the standard clinical candidate 2-methyl-6-phenylethynyl-pyridine (MPEP), and co-crystal 2-[2-(3-methoxyphenyl)ethynyl]-6-methyl-pyridine (M-MPEP). The top selected hits demonstrated optimal binding energies, molecular interactions, and favorable ADMET properties with a few toxicity liabilities, warranting further lead optimization and experimental validations. MD simulations validated their structural stability through RMSD, RMSF, and principal component analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and implications:<\/jats:title>\n                    <jats:p>Our findings provided compelling evidence for a structure-based drug design approach in developing potent small-molecule natural modulators for the treatment of neurodegenerative disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/rps.rps_61_25","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:00:10Z","timestamp":1785124810000},"page":"437-451","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Computational investigation for exploring botanical ingredients as potential negative allosteric modulators targeting metabotropic glutamate receptor 5"],"prefix":"10.4103","volume":"21","author":[{"given":"Pracheta","family":"Singh","sequence":"first","affiliation":[{"name":"Amity Institute of Pharmacy, Amity University Uttar Pradesh Lucknow Campus, Lucknow, Uttar Pradesh 226010, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan","family":"Patra","sequence":"additional","affiliation":[{"name":"Amity Institute of Pharmacy, Amity University Uttar Pradesh Lucknow Campus, Lucknow, Uttar Pradesh 226010, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz S.","family":"Saeedan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Aldossary","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Nazam","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"1","key":"R1-20260728","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/157015912799362805","article-title":"Therapeutic potential of metabotropic glutamate receptor modulators","volume":"10","author":"Hovels\u00f8","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"R2-20260728","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fnins.2015.00086","article-title":"The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies","volume":"9","author":"Terbeck","year":"2015","journal-title":"Front Neurosci"},{"issue":"6","key":"R3-20260728","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/ijms20061412","article-title":"The Role of metabotropic glutamate receptors in social behavior in rodents","volume":"20","author":"Zoicas","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"7","key":"R4-20260728","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1528-1167.2011.03082.x","article-title":"Metabotropic glutamate receptors in the thalamocortical network: strategic targets for the treatment of absence epilepsy","volume":"52","author":"Ngomba","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"R5-20260728","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.nbd.2011.01.022","article-title":"AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome","volume":"42","author":"Levenga","year":"2011","journal-title":"Neurobiol Dis"},{"key":"R6-20260728","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40673-018-0082-1","article-title":"Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study","volume":"5","author":"Fatemi","year":"2018","journal-title":"Cerebellum Ataxias"},{"key":"R7-20260728","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2013.12.019","article-title":"The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?","volume":"723","author":"Pitsikas","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"R8-20260728","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","volume":"20","author":"Rascol","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"R9-20260728","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s10072-021-05319-7","article-title":"Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson\u2019s disease: a meta-analysis","volume":"42","author":"Negida","year":"2021","journal-title":"Neurol Sci"},{"issue":"2","key":"R10-20260728","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12325-016-0468-5","article-title":"Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study","volume":"34","author":"Rutrick","year":"2017","journal-title":"Adv Ther"},{"issue":"7","key":"R11-20260728","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2016.0838","article-title":"Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial","volume":"73","author":"Quiroz","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"R12-20260728","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.114.222463","article-title":"Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression","volume":"353","author":"Lindemann","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-20260728","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2016.12.006","article-title":"Molecular insights into allosteric modulation of Class C G protein-coupled receptors","volume":"116","author":"Leach","year":"2017","journal-title":"Pharmacol Res"},{"key":"R14-20260728","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2014.09.022","article-title":"Structures of mGluRs shed light on the challenges of drug development of allosteric modulators","volume":"20","author":"Bennett","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"R15-20260728","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1208\/s12248-017-0093-5","article-title":"Integrated in silico fragment-based drug design: case study with allosteric modulators on metabotropic glutamate receptor 5","volume":"19","author":"Bian","year":"2017","journal-title":"AAPS J"},{"issue":"4","key":"R16-20260728","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/cn400005t","article-title":"Regulation of G protein-coupled receptors by allosteric ligands","volume":"4","author":"Lane","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"R17-20260728","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-pharmtox-010611-134525","article-title":"Drugs for allosteric sites on receptors","volume":"54","author":"Wenthur","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7511","key":"R18-20260728","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature13396","article-title":"Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain","volume":"511","author":"Dor\u00e9","year":"2014","journal-title":"Nature"},{"issue":"6","key":"R19-20260728","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/13543776.2017.1280466","article-title":"mGlu(5) negative allosteric modulators: a patent review (2013-2016)","volume":"27","author":"Emmitte","year":"2017","journal-title":"Expert Opin Ther Pat"},{"issue":"3","key":"R20-20260728","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/jm501642c","article-title":"Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2, 5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases","volume":"58","author":"Jaeschke","year":"2015","journal-title":"J Med Chem"},{"issue":"1","key":"R21-20260728","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/acs.jmedchem.7b01722","article-title":"Structure-based optimization strategies for G protein-coupled receptor (GPCR) allosteric modulators: a case study from analyses of new metabotropic glutamate receptor 5 (mGlu(5)) X-ray structures","volume":"62","author":"Christopher","year":"2019","journal-title":"J Med Chem"},{"issue":"12","key":"R22-20260728","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1021\/acs.jmedchem.7b00410","article-title":"Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinical evaluation","volume":"60","author":"Felts","year":"2017","journal-title":"J Med Chem"},{"issue":"15","key":"R23-20260728","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.bmcl.2010.06.075","article-title":"Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists","volume":"20","author":"Galambos","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"R24-20260728","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejmech.2017.03.071","article-title":"Discovery of 4-amino-3-arylsulfoquinolines, a novel non-acetylenic chemotype of metabotropic glutamate 5 (mGlu5) receptor negative allosteric modulators","volume":"133","author":"Galambos","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"16","key":"R25-20260728","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/acs.jmedchem.5b00892","article-title":"Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)","volume":"58","author":"Christopher","year":"2015","journal-title":"J Med Chem"},{"key":"R26-20260728","doi-asserted-by":"crossref","first-page":"691152","DOI":"10.3389\/fbioe.2021.691152","article-title":"Recent advances in the synthetic biology of natural drugs","volume":"9","author":"Li","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"R27-20260728","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/metabo2020303","article-title":"A historical overview of natural products in drug discovery","volume":"2","author":"Dias","year":"2012","journal-title":"Metabolites"},{"issue":"3","key":"R28-20260728","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"R29-20260728","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/0471141755.ph0911s46","article-title":"Natural products as a foundation for drug discovery","volume":"46","author":"Beutler","year":"2009","journal-title":"Curr Protoc Pharmacol"},{"issue":"4","key":"R30-20260728","doi-asserted-by":"crossref","first-page":"e1468","DOI":"10.1002\/wcms.1468","article-title":"Next-generation 3D pharmacophore modeling","volume":"10","author":"Schaller","year":"2020","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"issue":"4","key":"R31-20260728","first-page":"396","article-title":"Virtual screening in lead discovery and optimization","volume":"7","author":"Jain","year":"2004","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"D1","key":"R32-20260728","doi-asserted-by":"crossref","first-page":"D654","DOI":"10.1093\/nar\/gkac1008","article-title":"SuperNatural 3.0-a database of natural products and natural product-based derivatives","volume":"51","author":"Gallo","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"R33-20260728","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkae1093","article-title":"The Natural Products Atlas 3.0: extending the database of microbially derived natural products","volume":"53","author":"Poynton","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"R34-20260728","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J Med Chem"},{"issue":"W1","key":"R35-20260728","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"R36-20260728","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J Chem Inf Model"},{"issue":"Web Server issue","key":"R37-20260728","doi-asserted-by":"crossref","first-page":"W409","DOI":"10.1093\/nar\/gks378","article-title":"ZINCPharmer: pharmacophore search of the ZINC database","volume":"40","author":"Koes","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"R38-20260728","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J Med Chem"},{"issue":"15","key":"R39-20260728","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jcc.23905","article-title":"DOCK 6: impact of new features and current docking performance","volume":"36","author":"Allen","year":"2015","journal-title":"J Comput Chem"},{"issue":"43","key":"R40-20260728","doi-asserted-by":"crossref","first-page":"39417","DOI":"10.1021\/acsomega.2c05826","article-title":"Systematic investigation of docking failures in large-scale structure-based virtual screening","volume":"7","author":"Xu","year":"2022","journal-title":"ACS Omega"},{"issue":"2","key":"R41-20260728","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0022-2836(82)90153-X","article-title":"A geometric approach to macromolecule-ligand interactions","volume":"161","author":"Kuntz","year":"1982","journal-title":"J Mol Biol"},{"issue":"4","key":"R42-20260728","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcc.540130412","article-title":"Automated docking with grid-based energy evaluation","volume":"13","author":"Meng","year":"1992","journal-title":"J Comput Chem"},{"issue":"7","key":"R43-20260728","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"g_mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J Chem Inf Model"},{"issue":"20","key":"R44-20260728","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.1063\/1.481505","article-title":"A five-site model for liquid water and the reproduction of the density anomaly by rigid, nonpolarizable potential functions","volume":"112","author":"Mahoney","year":"2000","journal-title":"J Chem Phys"},{"issue":"3","key":"R45-20260728","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J Comput Phys"},{"issue":"4","key":"R46-20260728","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/npp.2009.201","article-title":"Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP","volume":"35","author":"Silverman","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"R47-20260728","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"R48-20260728","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.3390\/ijms24076311","article-title":"Quantum mechanical assessment of protein-ligand hydrogen bond strength patterns: insights from semiempirical tight-binding and local vibrational mode theory","volume":"24","author":"Madushanka","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"R49-20260728","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/jacs.1c11270","article-title":"Chemical evolution of natural product structure","volume":"144","author":"Grigalunas","year":"2022","journal-title":"J Am Chem Soc"},{"issue":"3","key":"R50-20260728","doi-asserted-by":"crossref","first-page":"e00113","DOI":"10.1128\/mSystems.00113-19","article-title":"Natural products and synthetic biology: where we are and where we need to go","volume":"4","author":"Kunakom","year":"2019","journal-title":"mSystems"},{"issue":"2","key":"R51-20260728","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1527-3458.2006.00149.x","article-title":"Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP","volume":"12","author":"Lea","year":"2006","journal-title":"CNS Drug Rev"}],"container-title":["Research in Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/RPS.RPS_61_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:02:41Z","timestamp":1785211361000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.4103\/RPS.RPS_61_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/rps.rps_61_25","relation":{},"ISSN":["1735-5362","1735-9414"],"issn-type":[{"value":"1735-5362","type":"print"},{"value":"1735-9414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-04-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}